diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM2015323-31diaendo-7125Research ArticleВопросы патогенезаPathogenesisНовые представления о нарушении глюкозостимулированной секреции инсулина при развитии сахарного диабета 2 типа. Клинические последствияNew concepts of glucose-induced insulin secretion in the development of type 2 diabetes: clinical implicationshttps://orcid.org/0000-0002-8175-7886ДедовИван ИвановичDedovIvan Ivanovich

доктор медицинских наук, профессор, акадкмик РАН, директор ФГБУ Эндокринологический научный центр, Москва.

MD, PhD, Professor, Academician of Russian academy of sciences, Director of Endocrinology research centre

dedov@endocrincentr.ruСмирноваОльга МихайловнаSmirnovaOlga Michailovna

доктор медицинских наук, профессор, главный научный сотрудник отделения программного обучения и лечения Института диабета ФГБУ ЭНЦ; профессор кафедры эндокринологии и диабетологии педиатрического факультета ГБОУ ВПО Первый Московский Государственный Медицинский университет им. И.М. Сеченова

MD, PhD, Professor, General research associate, Department of Program Education and Treatment, Endocrinology Research Centre; Department of Endocrinology and Diabetology, Pediatric Faculty, I.M.Sechenov First Moscow State Medical University

dr_smr@mail.ruКононенкоИрина ВладимировнаIrinaKononenko Vladimirovna

кандидат медицинских наук, старший научный сотрудник отделения программного обучения и лечения Института диабета ФГБУ ЭНЦ; ассистент кафедры эндокринологии и диабетологии педиатрического факультета ГБОУ ВПО Первый Московский Государственный Медицинский университет им. И.М. Сеченова

MD, PhD, Leading research associate, Department of Program Education and Treatment, Endocrinology Research Centre; associate professor, Department of Endocrinology and Diabetology, Pediatric Faculty, I.M.Sechenov First Moscow State Medical University

shakhtarina@bk.ruФГБУ "Эндокринологический научный центр" Минздрава РоссииРоссияEndocrinology Research Centre, MoscowRussian FederationФГБУ "Эндокринологический научный центр" Минздрава России; ГБОУ ВПО Первый Московский Государственный Медицинский университет им. И.М. СеченоваРоссияEndocrinology Research Centre, Moscow; Sechenov First Moscow State Medical UniversityRussian FederationФГБУ "Эндокринологический научный центр" Минздрава России; ГБОУ ВПО Первый Московский Государственный Медицинский университет им. И.М. СеченоваРоссияEndocrinology Research Centre, Moscow, Russian FederationRussian Federation2015010720151832331Copyright © Дедов И.И., Смирнова О.М., Кононенко И.В., 20152015Дедов И.И., Смирнова О.М., Кононенко И.В.Dedov I.I., Smirnova O.M., Irina K.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/7125

Распространенность сахарного диабета 2 типа (СД2) продолжает катастрофически увеличиваться. Патогенез СД2 активно изучается в течение последних лет. Особый интерес по-прежнему вызывает изменение секреции инсулина в ходе естественного развития заболевания и участие в этих процессах инкретинов. Появление новых препаратов, относящихся к группе инкретинов, ставит перед клиницистами важные вопросы об их месте в реальной клинической практике.

 

The prevalence of type 2 diabetes is increasing dramatically, and the pathogenesis of the disease has been studied extensively in recent years. Of particular interest, incretins are reported to cause changes in insulin secretion that affect the natural development of the disease. The emergence of new drugs that act via the incretin axis have led many clinicians to consider their place in clinical practice.

патогенезсекреция инсулинасигнальные пути действия препаратовpathogenesisthe insulin secretionsignaling pathwaysdrugs actionReferencesIDF Diabetes Atlas. 7-th edition, 2014. Available from: http://www.idf.org/diabetesatlasIDF Diabetes Atlas. 7-th edition, 2014. Available from: http://www.idf.org/diabetesatlasТкачук В.А., Воротников А.В. Молекулярные механизмы развития резистентности к инсулину. // Сахарный диабет. – 2014. – Т. 17. – №2 – С.29-40. [Tkachuk VA, Vorotnikov AV. Molecular Mechanisms of Insulin Resistance Development. Diabetes mellitus. 2014;17(2):29-40.] doi: 10.14341/DM2014229-40Ткачук В.А., Воротников А.В. Молекулярные механизмы развития резистентности к инсулину. // Сахарный диабет. – 2014. – Т. 17. – №2 – С.29-40. [Tkachuk VA, Vorotnikov AV. Molecular Mechanisms of Insulin Resistance Development. Diabetes mellitus. 2014;17(2):29-40.] doi: 10.14341/DM2014229-40DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care. 1992;15(3):318-368. doi: 10.2337/diacare.15.3.318DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care. 1992;15(3):318-368. doi: 10.2337/diacare.15.3.318Weigle DS. Pulsatile secretion of fuel-regulatory hormones. Diabetes. 1987;36(6):764–775. doi: 10.2337/diab.36.6.764Weigle DS. Pulsatile secretion of fuel-regulatory hormones. Diabetes. 1987;36(6):764–775. doi: 10.2337/diab.36.6.764Lefèbvre PJ, Paolisso G, Scheen AJ, et al. Pulsatility of insulin and glucagon release: physiological significance and pharmacological implications. Diabetologia. 1987;30(7):443–452. doi: 10.1007/BF00279610Lefèbvre PJ, Paolisso G, Scheen AJ, et al. Pulsatility of insulin and glucagon release: physiological significance and pharmacological implications. Diabetologia. 1987;30(7):443–452. doi: 10.1007/BF00279610Pfeifer MA, Halter JB, Porte D, Jr. Insulin secretion in diabetes mellitus. The American journal of medicine.70(3):579-588. doi: 10.1016/0002-9343(81)90579-9Pfeifer MA, Halter JB, Porte D, Jr. Insulin secretion in diabetes mellitus. The American journal of medicine.70(3):579-588. doi: 10.1016/0002-9343(81)90579-9Rorsman P, Renström E. Insulin granule dynamics in pancreatic beta cells. Diabetologia. 2003;46(8):1029–1045. doi: 10.1007/s00125-003-1153-1Rorsman P, Renström E. Insulin granule dynamics in pancreatic beta cells. Diabetologia. 2003;46(8):1029–1045. doi: 10.1007/s00125-003-1153-1Axelrod D. Selective imaging of surface fluorescence with very high aperture microscope objectives. J Biomed Opt. 2001;6(1):6–13. doi: 10.1117/1.1335689Axelrod D. Selective imaging of surface fluorescence with very high aperture microscope objectives. J Biomed Opt. 2001;6(1):6–13. doi: 10.1117/1.1335689Tsuboi T, Zhao C, Terakawa S, et al. Simultaneous evanescent wave imaging of insulin vesicle membrane and cargo during a single exocytotic event. Curr Biol. 2000;10(20):1307–1310. doi: 10.1016/S0960-9822(00)00756-9Tsuboi T, Zhao C, Terakawa S, et al. Simultaneous evanescent wave imaging of insulin vesicle membrane and cargo during a single exocytotic event. Curr Biol. 2000;10(20):1307–1310. doi: 10.1016/S0960-9822(00)00756-9Seino S, Shibasaki T, Minami K. Dinamics of insulin secretin and the clinical implication for obesity and diabetes. J Clin Invest. 2011;121(6):2118-25. doi: 10.1172/JCI45680Seino S, Shibasaki T, Minami K. Dinamics of insulin secretin and the clinical implication for obesity and diabetes. J Clin Invest. 2011;121(6):2118-25. doi: 10.1172/JCI45680Wollheim CB, Sharp GW. Regulation of insulin release by calcium. Physiol Rev. 1981;61(4):914–973.Wollheim CB, Sharp GW. Regulation of insulin release by calcium. Physiol Rev. 1981;61(4):914–973.Ashcroft FM. ATP-sensitive potassium channelopathies: focus on insulin secretion. J Clin Invest. 2005;115(8):2047–2058. doi: 10.1172/JCI25495Ashcroft FM. ATP-sensitive potassium channelopathies: focus on insulin secretion. J Clin Invest. 2005;115(8):2047–2058. doi: 10.1172/JCI25495Miki T, Nagashima K, Tashiro F, et al. Defective insulin secretion and enhanced insulin action in KATP channel-deficient mice. Proc Natl Acad Sci USA. 1998;95(18):10402-10406. doi: 10.1073/pnas.95.18.10402Miki T, Nagashima K, Tashiro F, et al. Defective insulin secretion and enhanced insulin action in KATP channel-deficient mice. Proc Natl Acad Sci USA. 1998;95(18):10402-10406. doi: 10.1073/pnas.95.18.10402Seghers V, Nakazaki M, DeMayo F,et al. Sur1 knockout mice. A model for K(ATP) channel-independent regulation of insulin secretion. J Biol Chem. 2000;275(13):9270-9277. doi: 10.1074/jbc.275.13.9270Seghers V, Nakazaki M, DeMayo F,et al. Sur1 knockout mice. A model for K(ATP) channel-independent regulation of insulin secretion. J Biol Chem. 2000;275(13):9270-9277. doi: 10.1074/jbc.275.13.9270Nauck MA. Unraveling the science of incretin biology. Am J Med. 2009;122(6 Suppl):S3-S10. doi: 10.1016/j.amjmed.2009.03.012Nauck MA. Unraveling the science of incretin biology. Am J Med. 2009;122(6 Suppl):S3-S10. doi: 10.1016/j.amjmed.2009.03.012Yasuda K, Inagaki N, Yamada Y, et al. Hamster gastric inhibitory polypeptide receptor expressed in pancreatic islets and clonal insulin-secreting cells: its structure and functional properties. Biochem Biophys Res Commun. 1994;205(3):1556-1562. doi: 10.1006/bbrc.1994.2844Yasuda K, Inagaki N, Yamada Y, et al. Hamster gastric inhibitory polypeptide receptor expressed in pancreatic islets and clonal insulin-secreting cells: its structure and functional properties. Biochem Biophys Res Commun. 1994;205(3):1556-1562. doi: 10.1006/bbrc.1994.2844Fujimoto W, Miki T, Ogura T, et al. Niflumic acid-sensitive ion channels play an important role in the induction of glucose-stimulated insulin secretion by cyclic AMP in mice. Diabetologia. 2009;52(5):863-872. doi: 10.1007/s00125-009-1306-yFujimoto W, Miki T, Ogura T, et al. Niflumic acid-sensitive ion channels play an important role in the induction of glucose-stimulated insulin secretion by cyclic AMP in mice. Diabetologia. 2009;52(5):863-872. doi: 10.1007/s00125-009-1306-yTakahashi T, Shibasaki T, Takahashi H, et al. Antidiabetic Sulfonylureas and cAMP Cooperatively Activate Epac2A. Sci Signal. 2013;6(298):ra94. doi: 10.1126/scisignal.2004581Takahashi T, Shibasaki T, Takahashi H, et al. Antidiabetic Sulfonylureas and cAMP Cooperatively Activate Epac2A. Sci Signal. 2013;6(298):ra94. doi: 10.1126/scisignal.2004581Marre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26(3):268-278. doi: 10.1111/j.1464-5491.2009.02666.xMarre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26(3):268-278. doi: 10.1111/j.1464-5491.2009.02666.xKubota A, Maeda H1, Kanamori A, et al. Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients. J Diabetes Investig. 2012 20;3(6):503-509. doi: 10.1111/j.2040-1124.2012.00221.xKubota A, Maeda H1, Kanamori A, et al. Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients. J Diabetes Investig. 2012 20;3(6):503-509. doi: 10.1111/j.2040-1124.2012.00221.xYabe D, Seino Y. Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe? J Diabetes Investig. 2014;5(5):475-7. doi: 10.1111/jdi.12229Yabe D, Seino Y. Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe? J Diabetes Investig. 2014;5(5):475-7. doi: 10.1111/jdi.12229Takahashi H, Shibasaki T, Park JH, et al. Role of Epac2A/Rap1 signaling in interplay between incretin and sulfonylurea in insulin secretion. Diabetes. 2015;64(4):1262-1272. doi: 10.2337/db14-0576Takahashi H, Shibasaki T, Park JH, et al. Role of Epac2A/Rap1 signaling in interplay between incretin and sulfonylurea in insulin secretion. Diabetes. 2015;64(4):1262-1272. doi: 10.2337/db14-0576Zhang CL, Katoh M, Shibasaki T, et al. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science. 2009;325(5940):607-10. doi: 10.1126/science.1172256Zhang CL, Katoh M, Shibasaki T, et al. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science. 2009;325(5940):607-10. doi: 10.1126/science.1172256Seino Y, Yabe D. GIP and GLP-1: incretin actions beyond pancreas. J Diabetes Investig. 2013;4(2):108-130. doi: 10.1111/jdi.12065Seino Y, Yabe D. GIP and GLP-1: incretin actions beyond pancreas. J Diabetes Investig. 2013;4(2):108-130. doi: 10.1111/jdi.12065Mukai E, Ishida H, Kato S, et al. Metabolic inhibition impairs ATP-sensitive K+ channel block by sulfonylurea in pancreatic beta-cells. Am J Physiol. 1998;274(1 Pt 1):E38-44.Mukai E, Ishida H, Kato S, et al. Metabolic inhibition impairs ATP-sensitive K+ channel block by sulfonylurea in pancreatic beta-cells. Am J Physiol. 1998;274(1 Pt 1):E38-44.

The authors declare that there are no conflicts of interest present.